Roba Gossan
Roba is a rheumatologist at Cochin Hospital APHP in Paris, France. Her main clinical and research interests include Inflammatory Rheumatic Diseases, MSK Ultrasound and Epidemiology. Roba is a member of the French Society of Rheumatology and the society’s young rheumatologists section (REF). She is a member of the EMEUNET Vi&GA Sub-Committee.
| Poster 1130 | Monday, October 27, 2025 10:30AM-12:30PM Abstract Session: (1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster Presenting author: K Tan (USA) Title: Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia  This study is the first to show that novel anti-obesity medications such as semaglutide and tirzepatide significantly lower serum urate levels in patients with gout, highlighting their potential dual benefit for managing both obesity and hyperuricemia. |
| Poster 1125 | Monday, October 27, 2025 10:30AM-12:30PM Abstract Session: (1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster Presenting author: B Coburn (USA) Title: Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout This study provides the first external validation of the EasyAllo tool, showing it can accurately predict the allopurinol dose needed to achieve target serum urate levels, offering a practical solution to improve gout management and overcome therapeutic inertia. |
| Poster 1992 | Tuesday, October 28, 2025 10:30AM-12:30PM Abstract Session: (1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II Presenting author: V Domingues (USA) Title: Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT This study provides safety data showing that methotrexate coadministration with pegloticase in uncontrolled gout is well tolerated without added hepatic or infectious risk, reinforcing its role in optimizing long-term efficacy and safety of biologic urate-lowering therapy. |
| Oral 2585 | Tuesday, October 28, 2025 1:00PM-1:15PM Abstract Session: Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (2585–2590) Presenting author: A Wheeler (USA) Title: The effect of prophylactic colchicine use on gene expression in gout This study uncovers gene expression changes associated with colchicine use in gout, revealing novel molecular pathways; particularly those related to innate immunity and cardiovascular regulation, that may explain its broader anti-inflammatory and cardioprotective effects. |
| Oral 0777 | Sunday, October 26, 2025 1:00PM-1:15PM Abstract Session: Miscellaneous Rheumatic & Inflammatory Diseases I: Focus on Auto-Inflammatory Diseases (0777–0782) Presenting author: K Byram (USA) Title: Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI) This study is important because it introduces the first consensus-based, severity-weighted disease activity index specifically designed for VEXAS syndrome, addressing a major unmet need for standardized disease assessment and future clinical trials. |
| Poster 0269 | Sunday, October 26, 2025 10:30AM-12:30PM Abstract Session: (0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I Presenting author: P García-Escudero (Spain) Title: Clinical Landscape and Severity Markers of VEXAS Syndrome in a Spanish Cohort: Findings from VEXASSER Study Group This study provides valuable insights into genotype-phenotype correlations in VEXAS syndrome, highlighting how specific UBA1 mutations may influence clinical presentation, hematologic features, and mortality; an important step toward personalized management of this rare disease. |
| Poster 0254 | Sunday, October 26, 2025 10:30AM-12:30PM Abstract Session: (0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I Presenting author: J Riley Lam (USA) Title: Comparative Outcomes in MAGIC Syndrome versus Relapsing Polychondritis Alone: A Propensity-Matched Analysis This study is the first large-scale comparative analysis of MAGIC syndrome versus isolated relapsing polychondritis, revealing a distinctive clinical profile with higher airway complications, which may redefine MAGIC as a more aggressive RP phenotype requiring targeted monitoring and management. |
| Poster 2044 | Tuesday, October 28, 2025 10:30AM-12:30PM Abstract Session: (2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III Presenting author: O Zeynep Avarbek (Turkey) Title: Infections and Associated Mortality in VEXAS Syndrome: A Systematic Review and Meta-Analysis This study systematically defines, for the first time, the spectrum and burden of infections in VEXAS syndrome, highlighting their major contribution to morbidity and mortality and underscoring the need for tailored infection monitoring and prophylactic strategies in this high-risk population. |